We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in MM

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in MM"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

SymBio Pharmaceuticals Limited has announced that it has achieved first patient enrollment and started a phase 2 clinical trial on December 26 for bendamustine hydrochloride (SyB L-0501) in refractory and relapsed multiple myeloma (MM) patients in Japan.

The number of multiple myeloma patients in Japan is estimated to be around 13,000, with an equal number of refractory/relapsed and frontline patients.

Regarding SyB L-0501 development in MM, SymBio plans to prioritize development in refractory/relapsed MM patients who were previously treated with other oncology drugs due to the high unmet medical need.

In Japan, SymBio received marketing approval of TREAKISYM® (SyB L 0501) in October, 2010, for the treatment of patients with refractory/relapsed low-grade non-Hodgkin’s lymphoma 2 (NHL) and mantle cell lymphoma (MCL).

Working with Eisai Co. Ltd., TREAKISYM® is expected to achieve rapid market penetration in Japan.

SymBio has also initiated phase 2 trials for SyB L-0501 in refractory/relapsed intermediate and high-grade non-Hodgkin’s lymphoma patients.

The Company continues to pursue other indications for TREAKISYM® in the hematology space as nimbly as possible in order to maximize the potential of this ‘pipeline within a molecule’ and address other unmet medical needs in patients.

SymBio’s financial forecast for FY 2011 will not be revised due to the acceptance of clinical trial notification.